Signios Bio and Illumina Announce Winners of the Illumina-Signios Bio Proteomics Grant Program

Signios Biosciences ("Signios Bio"), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced the winners of the ...
IPWatchdog

10x Genomics and Prognosys Biosciences Allege Illumina Infringed Four Spatial Transcriptomics Patents

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...
San Diego Union-Tribune

Investor Carl Icahn waging another proxy battle over Illumina’s failed acquisition of Grail

Less than 24 hours after biotech giant Illumina said it would divest early cancer detection firm Grail, activist investor Carl Icahn published a letter announcing he’s ready to do battle against the ...
Nasdaq

Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection. “This acquisition is ...
GEN

Illumina to Divest of Grail after Appeals Court Defeat

Battered by more than three years of opposition from authorities in the United States and Europe—most recently an unfavorable federal appeals court decision on Friday—Illumina said it will divest ...
Reuters

Illumina appeals FTC order to divest cancer test maker Grail

WASHINGTON, June 5 (Reuters) - Illumina (ILMN.O), opens new tab on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest ...
FierceBiotech

Illumina shareholders vote in one Carl Icahn nominee over current chairman, reject executive pay proposal

Activist investor Carl Icahn’s proxy battle against Illumina reached its conclusion Thursday with wins and losses on both sides. Icahn spent the last several weeks attempting to rally support for an ...
FierceBiotech

Illumina facing proxy battle led by activist investor Carl Icahn over Grail acquisition: WSJ

Illumina is reportedly the target of an upcoming proxy battle, stemming from the sequencing giant’s decision to plow ahead in its $8 billion reacquisition of former spinout Grail in 2021 in defiance ...
Times of San Diego

San Diego Genetic Sequencing Pioneer Illumina Fends Off Carl Icahn Proxy Bid

Illumina CEO Francis deSouza unveils the NovaSeq X Series sequencing platforms in 2022. Courtesy of the company San Diego genetic-sequencing pioneer Illumina on Monday challenged Carl Icahn’s bid for ...
Scripps News

Illumina Supports Enhanced Genomics-Enabled Discovery and Training Programs at UC San Diego

Scripps Institution of Oceanography at the University of California San Diego announced today that Illumina, recognized as a global leader in the development and application of genomic technology to ...
San Diego Union-Tribune

Illumina pushes back against activist investor Carl Icahn’s bid for board seats

San Diego biotech company Illumina is pushing back against well-known activist investor Carl Icahn, who intends to launch a proxy fight for board seats over the San Diego company’s “ill-advised” ...